Loading...

Altamira Therapeutics Ltd.

CYTO•NASDAQ
Healthcare
Biotechnology
$0.07
$-0.23(-76.67%)

Altamira Therapeutics Ltd. (CYTO) Stock Overview

Explore Altamira Therapeutics Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.2/100

Key Financials

Market Cap1.1M
P/E Ratio-0.02
EPS (TTM)$1.82
ROE7.83%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.07

CYTO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Altamira Therapeutics Ltd. (CYTO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.07.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.02 and a market capitalization of 1.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for CYTOStats details for CYTO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CYTOAnalyst Recommendations details for CYTO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

CEO

Thomas Meyer

Employees

10

Headquarters

Clarendon House, Hamilton

Founded

2014

Frequently Asked Questions

;